What treatment you receive depends on how fast your cancer is growing and how far it has spread

Prostate cancer treatment is not one-size-fits-all. A slow-growing cancer found early may need only monitoring. A faster cancer or one that has spread beyond the prostate may call for surgery, radiation, hormone therapy, or chemotherapy—sometimes in combination. Your age, overall health, and what side effects matter most to you also shape the decision. The goal is to weigh how much the cancer threatens your life against how much treatment will affect your quality of life.

Your urologist or oncologist will order imaging and blood tests to determine how aggressive your cancer is. The Gleason score (which grades how abnormal the cancer cells look under a microscope) and the PSA level (a protein your prostate makes) help predict whether the cancer will grow slowly or quickly. These two measures, plus the size and location of the tumor, determine your risk category—low, intermediate, or high—and guide which treatments make sense.

Key Takeaways

  • Low-risk prostate cancers often do not need immediate treatment; many men choose active surveillance, which means regular PSA tests and biopsies to watch for growth.
  • Surgery to remove the prostate (radical prostatectomy) and radiation therapy are the main curative treatments for cancer confined to the prostate.
  • Hormone therapy slows or stops cancer growth by blocking testosterone, and is often used alongside radiation or for advanced cancer.
  • Side effects vary by treatment: surgery and radiation can cause incontinence and erectile dysfunction; hormone therapy causes hot flashes and fatigue.
  • Your age, life expectancy, cancer risk level, and personal priorities determine which treatment path makes sense for you.

Active Surveillance: Watching a slow-growing cancer without treating it yet

If your cancer is low-risk—a low Gleason score, PSA under 10, and cancer confined to one side of the prostate—your doctor may recommend active surveillance instead of immediate treatment. This means you have regular PSA blood tests (usually every three to six months), digital rectal exams, and periodic prostate biopsies to check whether the cancer is growing. If tests show the cancer is becoming more aggressive, you can then move to surgery or radiation.

Active surveillance avoids the side effects of treatment—incontinence, erectile dysfunction, bowel problems—in men whose cancer may never cause harm. Studies show that many men with low-risk prostate cancer live decades without the cancer spreading or causing symptoms. However, active surveillance requires commitment: you must keep all appointments and be willing to accept the small risk that the cancer grows between check-ups without being caught immediately.

Active surveillance is not the same as doing nothing. You are under close medical watch. If you miss appointments or feel uncomfortable with the uncertainty, surgery or radiation may be a better fit for you psychologically, even if the cancer risk is low.

Radical Prostatectomy: Surgical removal of the prostate

A radical prostatectomy removes the entire prostate gland, the seminal vesicles, and nearby lymph nodes. It is the main surgical option for cancer confined to the prostate and offers the best chance of cure if all cancer is removed. The surgery can be done three ways: open surgery (a single incision in the abdomen or between the scrotum and anus), laparoscopic (several small incisions and a camera to guide the surgeon), or robot-assisted (laparoscopic with a robotic arm that the surgeon controls). Robot-assisted surgery is now the most common approach in the United States because it allows precise movement and often results in less blood loss and shorter hospital stays.

Recovery takes four to six weeks for most men. You will have a catheter (a tube to drain urine) for one to two weeks after surgery. Pathology results come back within one to two weeks and show whether all cancer was removed and whether it had spread to the lymph nodes.

The main side effects are incontinence and erectile dysfunction. About 10 to 20 percent of men experience long-term urinary incontinence (leaking urine); most recover continence within the first year. Erectile dysfunction occurs in 20 to 50 percent of men depending on age and whether the surgeon was able to spare the nerves that control erection. Medications like sildenafil (Viagra) or penile implants can help, but recovery of natural function takes months to years if it happens at all.

Radiation Therapy: Killing cancer cells with high-energy beams

External beam radiation therapy (EBRT) aims focused radiation at the prostate from outside the body. Treatment is given five days a week for seven to nine weeks as an outpatient. Modern techniques like intensity-modulated radiation therapy (IMRT) and image-guided radiation therapy (IGRT) shape the beam to match the prostate's contours, reducing damage to surrounding tissue. Brachytherapy is an alternative in which radioactive seeds or pellets are implanted directly into the prostate; it is often completed in one or two procedures and works well for low- to intermediate-risk cancers.

Radiation is often combined with hormone therapy (see below), especially for intermediate- and high-risk cancers. The hormone therapy shrinks the prostate and makes it easier to target with radiation, and it kills cancer cells that may have spread beyond the prostate.

Side effects during treatment include fatigue, urinary urgency and frequency, and loose stools or rectal irritation. Most resolve within weeks to months after treatment ends. Long-term side effects include erectile dysfunction (in 30 to 50 percent of men) and, rarely, urinary incontinence or bowel problems. Radiation also carries a small risk of secondary cancer (a new cancer caused by the radiation itself) years later, though this risk is low.

Hormone Therapy: Blocking testosterone to slow cancer growth

Hormone therapy (also called androgen deprivation therapy or ADT) works by lowering testosterone or blocking its effects on cancer cells. Prostate cancer cells need testosterone to grow, so cutting off that supply slows or stops growth. Hormone therapy is not a cure on its own but is used alongside radiation for intermediate- and high-risk cancers, and as the main treatment for cancer that has spread beyond the prostate.

Medications include GnRH agonists (leuprolide, goserelin, triptorelin) given as injections every one to three months, GnRH antagonists (degarelix), and antiandrogens (bicalutamide, enzalutamide, abiraterone) taken as pills. Your doctor may use one drug or a combination. Treatment typically lasts six months to three years when combined with radiation, or longer for advanced cancer.

Side effects include hot flashes (in 50 to 80 percent of men), fatigue, weight gain, loss of muscle mass, decreased libido, erectile dysfunction, and mood changes. Bone density can decrease, raising the risk of fractures; your doctor may recommend bone density screening and calcium and vitamin D supplements. Most side effects improve or resolve after treatment ends, though some men experience lasting sexual dysfunction.

Chemotherapy and newer drugs for advanced cancer

If prostate cancer has spread to bones or distant organs, or if it stops responding to hormone therapy, chemotherapy or newer targeted drugs may be used. Docetaxel is a chemotherapy drug given intravenously every three weeks for up to ten cycles. It can extend survival in men with advanced cancer but causes side effects including fatigue, hair loss, nausea, and increased infection risk.

Newer options include abiraterone and enzalutamide, which block testosterone at different points in the body and work even when standard hormone therapy has stopped working. Sipuleucel-T is a cancer vaccine that trains the immune system to attack prostate cancer cells; it is given as three infusions two weeks apart. These drugs often extend survival by months to a few years and may have fewer side effects than chemotherapy, though they are expensive and not all insurance plans cover them.

Choosing a treatment: What matters most to you

The "best" treatment depends on balancing cancer risk against side effects and your personal priorities. A 75-year-old man with a low-risk cancer and a ten-year life expectancy may reasonably choose active surveillance to avoid surgery or radiation. A 55-year-old with a high-risk cancer and a 30-year life expectancy may choose surgery or radiation to maximize the chance of cure, accepting the risk of incontinence or erectile dysfunction.

Talk with your doctor about your life expectancy (based on your age and overall health), how aggressive your cancer is, and what side effects matter most to you. Some men prioritize avoiding incontinence; others prioritize preserving sexual function. Some want the most aggressive treatment possible; others prefer to avoid treatment if the cancer is slow-growing. There is no single right answer—only the answer that fits your situation and values.

If you are diagnosed with prostate cancer, ask your doctor for a referral to an oncologist or urologist who specializes in prostate cancer. A second opinion is reasonable and often recommended, especially before major surgery or radiation. Treatment decisions can take weeks; there is usually time to gather information and think carefully.

Frequently Asked Questions

Can prostate cancer come back after surgery or radiation?

Yes. Cancer can recur locally (in tissue near where the prostate was) or spread to distant sites. Recurrence is detected by rising PSA levels after treatment. If PSA rises after surgery, radiation or hormone therapy may be offered. If PSA rises after radiation, surgery is rarely an option, but hormone therapy or other drugs can be used. Regular PSA monitoring after treatment is important to catch recurrence early.

What is the difference between active surveillance and watchful waiting?

Active surveillance involves regular PSA tests, rectal exams, and biopsies to monitor the cancer closely and treat it if it grows. Watchful waiting is less intensive monitoring, usually used in older men or those with limited life expectancy, with the goal of treating symptoms if they develop rather than preventing spread. Active surveillance is more common in younger men with low-risk cancer.

Will hormone therapy make me infertile?

Hormone therapy lowers testosterone and can reduce sperm production. If you want to father children, discuss sperm banking before starting treatment. Fertility may recover after treatment ends, but recovery is not may provide. Talk with your doctor about your options before beginning hormone therapy.

How long does treatment take, and when can I return to normal activities?

Surgery recovery takes four to six weeks before returning to light activity; full recovery takes two to three months. Radiation is five days a week for seven to nine weeks but does not prevent daily activities. Hormone therapy is ongoing (months to years) and does not restrict activity, though fatigue may limit what you feel like doing. Brachytherapy recovery is one to two weeks. Ask your surgeon or radiation oncologist for a specific timeline based on your treatment.

What happens if I decide not to treat my prostate cancer?

If your cancer is low-risk and slow-growing, many men live normal lifespans without treatment. However, if you choose not to treat and the cancer grows, your options narrow—it becomes harder to cure. Active surveillance allows you to monitor the cancer and treat it later if needed, which is different from refusing all monitoring. Discuss the risks and benefits of each approach with your doctor.